Patents Assigned to Incyte Pharmaceuticals, Inc.
-
Patent number: 7803373Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.Type: GrantFiled: May 20, 2008Date of Patent: September 28, 2010Assignee: Incyte Pharmaceuticals, Inc.Inventors: Roger T. Coleman, Olga Bandman, Craig G. Wilde
-
Publication number: 20070105171Abstract: The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.Type: ApplicationFiled: October 2, 2006Publication date: May 10, 2007Applicants: Incyte Pharmaceuticals, Inc., Genentech, Inc.Inventors: Olga Bandman, Jennifer Hillman, Henry Yue, Karl Guegler, Neil Corley, Y. Tang, Purvi Shah
-
Publication number: 20070026449Abstract: The present invention provides a human sodium-dependent phosphate cotransporter (NAPTR) and polynucleotides which identify and encode NAPTR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NAPTR and a method for producing NAPTR. The invention also provides for agonists, antibodies, or antagonists specifically for NAPTR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NAPTR for the treatment of diseases associated with the expression of NAPTR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NAPTR. The invention also provides a method for treating disorders associated with decreased phosphate levels by administering NAPTR and a method for treating disorders associated with increased phosphate levels by administering antagonists to NAPTR.Type: ApplicationFiled: September 25, 2006Publication date: February 1, 2007Applicant: Incyte Pharmaceuticals, IncInventors: Preeti Lal, Olga Bandman
-
Publication number: 20050181404Abstract: The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.Type: ApplicationFiled: January 27, 2005Publication date: August 18, 2005Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer Hillman, Henry Yue, Karl Guegler, Neil Corley, Y. Tang, Purvi Shah
-
Publication number: 20050042724Abstract: The present invention provides a human sodium-dependent phosphate cotransporter (NAPTR) and polynucleotides which identify and encode NAPTR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NAPTR and a method for producing NAPTR. The invention also provides for agonists, antibodies, or antagonists specifically for NAPTR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NAPTR for the treatment of diseases associated with the expression of NAPTR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NAPTR. The invention also provides a method for treating disorders associated with decreased phosphate levels by administering NAPTR and a method for treating disorders associated with increased phosphate levels by administering antagonists to NAPTR.Type: ApplicationFiled: June 25, 2004Publication date: February 24, 2005Applicant: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Olga Bandman
-
Patent number: 6855811Abstract: The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.Type: GrantFiled: September 26, 2001Date of Patent: February 15, 2005Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Henry Yue, Karl J. Guegler, Neil C. Corley, Y. Tom Tang, Purvi Shah
-
Publication number: 20040111674Abstract: Disclosed are methods, media and systems for graphically displaying computer-based biomolecular sequence information. Generally, biomolecular sequence information may be graphically depicted in a variety of different forms in accordance with the present invention. The sequence information may be composed of nucleotide or amino acid sequence information or both. The graphical depictions may be in several different formats providing different information relating to the sequences, and may be displayed in one or more screens of a computer user interface.Type: ApplicationFiled: November 3, 2003Publication date: June 10, 2004Applicants: Incyte Genomics, Inc., Incyte Pharmaceuticals, Inc.Inventors: Alex George Koleszar, Frank D. Russo, Joe Don Heath, Stephanie F. Berry, Rachel J. Wright, Peter A. Covitz, Yvonne R. Boldt, Lee Crawford
-
Publication number: 20040086936Abstract: The invention provides a human preproneurotensin/neuromedin N (HPPN) and polynucleotides which identify and encode HPPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HPPN.Type: ApplicationFiled: August 9, 2001Publication date: May 6, 2004Applicant: Incyte Pharmaceuticals, IncInventors: Preeti Lal, Purvi Shah, Neil C. Corley
-
Publication number: 20040024535Abstract: The present invention provides relational database systems for storing biomolecular sequence information together with biological annotations detailing the source of the sequence information, and associated reagent information. The acquisition, storage and access of reagent information associated with databased biomolecular sequence information is a particular advantage of the present invention. Such reagent information identifies genetic information and materials which may be made available to a user of the relational database system of the present invention for further application in research, therapeutic pharmaceutical development or other fields. The reagent information aspect of the present invention is preferably used in conjunction with a biomolecular sequence relational database system.Type: ApplicationFiled: February 4, 2003Publication date: February 5, 2004Applicant: Incyte Pharmaceuticals, Inc.Inventors: Stephen E. Lincoln, Tod M. Klingler, Landes C. Wong, Scott R. Panzer, David M. Hodgson, Laura Y. Ito, Andrew D. Ament, Richard Cathcart, Helen E. Jolley, Ingrid E. Akerblom, Brian M. McKelligon, Mayank K. Thanawala
-
Publication number: 20030237110Abstract: The present invention provides purified, corn seedling-derived polynucleotides (cdps) which encode corn seedling-derived polypeptides (CDPs). The invention also provides for the use of cdps or their complements, oligonucleotides, or fragments in methods for determining altered gene expression, to recover regulatory elements, and to follow inheritance of desirable characteristics through hybrid breeding programs. The invention further provides for vectors and host cells containing cdps for the expression of CDPs. The invention additionally provides for (i) use of isolated and purified CDPs to induce antibodies and to screen libraries of compounds and (ii) use of anti-CDP antibodies in diagnostic assays.Type: ApplicationFiled: August 6, 2001Publication date: December 25, 2003Applicant: Incyte Pharmaceuticals, Inc.Inventors: Raghunath V. Lalgudi, Laura Y. Ito, Bradley K. Sherman
-
Publication number: 20030170219Abstract: The invention provides human disease associated protein kinases and polynucleotides (collectively designated DAPK) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing and treating disorders associated with expression of human disease associated protein kinases.Type: ApplicationFiled: January 24, 2001Publication date: September 11, 2003Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Preeti Lal, Surya K. Goli, Purvi Shah
-
Publication number: 20030166847Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human leptin receptor gene-related protein (LRGRP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding LRGRP. The invention also provides for the use of substantially purified LRGRP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of LRGRP. Additionally, the invention provides for the use of antisense molecules to LRGRP in pharmaceutical compositions for treatment of diseases associated with the expression of LRGRP.Type: ApplicationFiled: November 5, 2001Publication date: September 4, 2003Applicant: Incyte Pharmaceuticals, Inc.Inventors: Bernard Bailleul, A. Donny Strosberg, Ingrid E. Akerblom
-
Publication number: 20030166043Abstract: The present invention provides a novel human tubby homolog (NHT) and polynucleotides which identify and encode NHT. The invention also provides expression vectors, host cells, agonists, antibodies, or antagonists. The invention also provides methods for treating disorders associated with appetite and eating.Type: ApplicationFiled: February 12, 2001Publication date: September 4, 2003Applicant: Incyte Pharmaceuticals, Inc.Inventors: Samuel T. Labrie, Preeti Lal, Lynn E. Murry
-
Publication number: 20030166199Abstract: The invention provides a human serine dehydratase homolog (SDHH) and polynucleotides which identify and encode SDHH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of SDHH.Type: ApplicationFiled: August 8, 2001Publication date: September 4, 2003Applicant: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Neil C. Corley, Karl J. Guegler, Chandra Patterson
-
Publication number: 20030147893Abstract: The present invention provides a novel human integral membrane (TMP-1) and polynucleotides which identify and encode TMP-1. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TMP-1 and a method for producing TMP-1. The invention also provides for agonists, antibodies, or antagonists specifically binding TMP-1, and their use, in the prevention and treatment of diseases associated with expression of TMP-1. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TMP-1 for the treatment of diseases associated with the expression of TMP-1. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding TMP-1.Type: ApplicationFiled: October 2, 2001Publication date: August 7, 2003Applicant: Incyte Pharmaceuticals, IncInventors: Jennifer L. Hillman, Surya K. Goli
-
Publication number: 20030118995Abstract: The present invention provides four human Rab and Rab-associated proteins (designated collectively as HRAB) and polynucleotides which identify and encode HRAB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HRAB and a method for producing HRAB. The invention also provides for use of HRAB and agonists, antibodies, or antagonists specifically binding HRAB, in the prevention and treatment of diseases associated with expression of HRAB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HRAB for the treatment of diseases associated with the expression of HRAB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HRAB.Type: ApplicationFiled: September 28, 2001Publication date: June 26, 2003Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Janice Au-Young
-
Publication number: 20030119730Abstract: The invention provides two human phospholipid binding proteins (PLBP) and polynucleotides which identify and encode PLBP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of PLBP.Type: ApplicationFiled: June 11, 2001Publication date: June 26, 2003Applicant: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Jennifer L. Hillman, Neil C. Corley, Purvi Shah
-
Publication number: 20030099612Abstract: The present invention provides a human microtubule-associated protein (hLC3) and the polynucleotides which identify and encode hLC3. The invention also provides genetically engineered expression vectors, host cells, and a method for producing hLC3. The invention also provides hLC3 as well as agonists, antibodies, and antagonists of hLC3, and the use thereof for the prevention and treatment of diseases associated with the expression of hLC3. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding hLC3 for the treatment of diseases associated with the expression of hLC3. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding hLC3.Type: ApplicationFiled: July 12, 2001Publication date: May 29, 2003Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6553317Abstract: The present invention provides relational database systems for storing biomolecular sequence information together with biological annotations detailing the source of the sequence information, and associated reagent information. The acquisition, storage and access of reagent information associated with databased biomolecular sequence information is a particular advantage of the present invention. Such reagent information identifies genetic information and materials which may be made available to a user of the relational database system of the present invention for further application in research, therapeutic pharmaceutical development or other fields. The reagent information aspect of the present invention is preferably used in conjunction with a biomolecular sequence relational database system.Type: GrantFiled: March 4, 1998Date of Patent: April 22, 2003Assignee: Incyte Pharmaceuticals, Inc.Inventors: Stephen E. Lincoln, Tod M. Klingler, Landes C. Wong, Scott R. Panzer, David M. Hodgson, Laura Y. Ito, Andrew D. Ament, Richard Cathcart, Helen E. Jolley, Ingrid E. Akerblom, Brian M. McKelligon, Mayank K. Thanawala
-
Publication number: 20030044401Abstract: The present invention provides a human glutathione s-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.Type: ApplicationFiled: February 14, 2001Publication date: March 6, 2003Applicant: Incyte Pharmaceuticals, Inc.Inventors: Surya K. Goli, Jennifer L. Hillman